Antiherpesvirus drugs: A promising spectrum of new drugs and drug targets

Nature Reviews Drug Discovery

Volumn 2, Issue 4, 2003, Pages 278-288

  Coen, Donald M ^a   Schaffer, Priscilla A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BAY 57 1293; BENZIMIDAVIR; BILS 179 BS; CIDOFOVIR; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; DNA POLYMERASE; DNA PRIMASE; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; HELICASE; IDOXURIDINE; PENCICLOVIR; PNU 183792; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSCOVITINE; T 0902611; THIAZOLE DERIVATIVE; THYMIDINE KINASE; TOMEGLOVIR; TRIFLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VIDARABINE; VIRUS PROTEIN; DNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE TARGETING; GENITAL HERPES; HERPES SIMPLEX KERATITIS; HERPES VIRUS INFECTION; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RETINITIS; REVIEW; STOMATITIS; VIRION; VIRUS ENCEPHALITIS; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANTIBIOTIC RESISTANCE; DRUG ANTAGONISM; DRUG EFFECT; HERPES VIRUS; PATHOGENICITY;

ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MICROBIAL; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS;

EID: 0037394125     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1065     Document Type: Review

References (77)

1. Straus, S. E. in Mandell, Douglas and Bennet's Principles and Practice of Infectious Diseases (eds Mandell, G. L., Bennet, J. E. & Dolin, R.) 1557-1564 (Churchill Livingstone, London,2000).
2. Weibel, R. E. et al. Live attenuated varicella virus vaccine: Efficacy trial in healthy children. N. Engl. J. Med. 310, 1409-1415 (1984).
3. Gershon, A. A., Steinberg, S. P. & Gelb, L. Live attentuated varicella vaccine use in immunocompromised children and adults. Pediatrics 78, 757-762 (1986).
4. Kaufman, H. E, Martola, E. & Dohlman, C. Use of 5 lodo-2′- deoxyuridine (IDU) in treatment of herpes simplex keratitis. Am. J. Opthalmol. 6, 235-239 (1962).
5. Reyes, M. et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and acquired immunodeficiency clinics. Arch. Intern. Med. 163, 76-80 (2003).
6. Jabs, D. A., Enger, C., Dunn, J, P. & Forman, M. S. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J. Infect. Dis. 177, 770-773 (1998).
7. Boivin, G. et al. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 184, 1598-1602 (2001).
8. Pertel, P.E. & Spear, P. G. Modified entry and syncytium formation by herpes simplex virus type 1 mutants selected for resistance to heparin inhibition. Virology 226, 22-33 (1996).
9. Orozco-Topete, R. et al. Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS. Antiviral Res. 35, 91-103 (1997).
10. Spear, P. G., Eisenberg, R. J. & Cohen, G. H. Three classes of cell surface receptors for α herpesvirus entry. Virology 275, 1-8 (2000).
11. Carfi, A. et al. Human herpes virus glycoprotein D bound to the human receptor HveA, Mol. Cell 8, 169-179 (2001).
12. Azad, R. F., Driver, V. B., Tanaka, K., Crooke, R. M. & Anderson, K. P. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37, 1945-1954 (1993).
13. Mulamba, G. B., Hu, A., Azad, R. F., Anderson, K. P. & Coen, D. M. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomiversen (ISIS 2922). Antimicrob. Agents Chemother, 42, 971-973 (1998).
14. Albin, R. et al. SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2. Antiviral Res. 35, 139-146 (1997).
15. Boulware, S. L., Bronstein, J. C., Nordby, E. C. Weber, P. C. Identification and characterization of a benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antiviral Res. 51, 111-125 (2001).
16. Brideau, R. J. et al. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. 54, 19-28 (2002).
17. Oien, N. L. et al. Broad-spectrum antiherpesvirus activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. 46, 724-730 (2002).
18. Thomsen, D. R. et al. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihyroquinolines, a novel class of herpesvirus antivirals. J. Virol. 77, 1868-1876 (2003).
19. Spector, F. C., Liang, L., Giordano, H., Sivaraja, M. & Petersen, M. G. Inhibition of herpes simplex virus replication by a 2-amino-thioazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. Viral. 72, 6979-69897 (1998).
20. Crute, J. E. et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nature Med. 8, 386-391 (2002).
21. Kleymann, G. et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature Med. 8, 391-398 (2002).
22. Chen, X. et al. SAR studies of a novel series human cytomegalovirus primase inhibitors. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract F-1672 (Chicago, 2001).
23. Powers, J. P. et al, Design of T0902611. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract F-1673 (Chicago, 2001).
24. Conen, H. A., Gaudreau, P, Brazeau, P. & Langelier, Y. Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2. Nature 321, 441-443 (1986).
25. Dutia, B. M., Frame, M. C., Subak-Sharpe, J. H., Clark, W. N. & Marsden, H. S. Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature 321, 439-441 (1986).
26. McClements, W. et al. Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation. Virology 162, 270-273 (1988).
27. Paradis, H., Gaudreau, P, Brazeau, P & Langelier, Y. Mechanism of inhibition of herpes simplex virus (HSV) ribonucleotide reducatse by a nonapeptide corresponding to the carboxy-terminus of its subunit 2. J. Biol. Chem. 263, 16045-16050 (1988).
28. Liuzzi, M. et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372, 695-698 (1994).
29. Moss, N. et al. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. J. Med. Chem. 39, 4173-4180 (1996).
30. Bonneau, A. M. et al. Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates. J. Virol. 70, 787-793 (1996).
31. Marsden, H. S. et al. Role of the carboxy terminus of herpes simplex virus type 1 DNA polymerase in its interaction with UL42. J. Gen. Virol. 75, 3127-3135 (1994).
32. Digard, P et al. Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface. Proc. Natl Acad. Sci. 92, 1456-1460 (1995).
33. Loregian, A. et al, Intranuclear delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin. Proc. Natl Acad. Sci. USA 96, 5221-5226 (1999).
34. Zuccola, H. Z., Filman, D. J., Coen, D. M. & Hogle, J. M. The crystal structure of an unusual processivity factor, herpes simplex virus UL42, bound to the C-terminus of its cognate polymerase. Mol. Cell 5, 267-278 (2000).
35. Bridges, K. G., Chow, C. S. & Coen, D. M. Identification of crucial hydrogen-bonding residues for the interaction of herpes simpex virus DNA polymerase subunits via peptide display, mutational, and calorimetric approaches. J. Virol. 75, 4990-4998 (2001).
36. Pilger, B. D., Cui, C. & Coen, D. M. Inhibition of HSV DNA polymerase subunit interaction by small molecules. 27th International Herpesvirus Workshop, Abstract 5.10 (Cairns, Australia, 2002).
37. Welch, A. R., Woods, A. S., McNally, L. M., Cotter, R. J. & Gibson, W. A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc. Natl Acad. Sci. USA 88, 10792-10796 (1991).
38. Liu, F. Y. & Roizman, B. The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate. J. Virol. 65, 5149-5156 (1991).
39. Chen, P et al. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell 86, 835-843 (1996).
40. Shen, H. S. et al. Three-dimensional structure of human cytomegalovirus protease. Nature 383, 279-282 (1996).
41. Qiu, X. et al. Unique fold and active site in cytomegalovirus protease. Nature 383, 275-279 (1996).
42. Tong, L. et al. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 383, 272-275 (1996).
43. Akanitapichat, P & Bastow, K. F. The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus. Antiviral Res. 53, 113-126 (2002).
44. van Zeijl, M. et al. Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. J. Virol. 74, 9054-9061 (2000).
45. Newcomb, W, W. & Brown, J. C. Inhibition of herpes simplex virus replication by WAY-150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. J. Virol. 76, 10084-10088 (2002).
46. Krosky, P. M. et al. Resistance of human cytomegalovirus to benzimidazole nucleoside analogs maps to two open reading frames: UL89 and UL56. J. Virol. 72, 4721-4728 (1998).
47. Underwood, M. R. et al. Inhibition of HCMV DNA maturation by a henzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72, 717-725 (1998).
48. Reefschlaeger, J. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48, 757-767 (2001).
49. Buerger, I. et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75, 9077-9086 (2001).
50. Nagelschmitz, J., Moeller, J. G., Stass, H. H., Wandel, C. & Kuhlmann, J. Safety, tolerability, and pharmacokinetics of single oral doses of BAY 38-4766: a novel, nonnucleosidic inhibitor of human cytomegalovirus. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract F-945 (San Francisco, 1999).
51. Boyd, F. L. et al. Synthesis and evaluation of a series of 1-benzimidazole pyranosides as anti-human cytomegalovirus agents. 218th American Chemical Society National Meeting. MEDI-283 (New Orleans, 1999).
52. Biron, K. K. et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46, 2365-2372 (2002).
53. Baek, M. C., Krosky, P. M., He, Z. & Coen, D. M. Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase: importance of the P+5 position. J. Biol. Chem. 277, 29593-29599 (2002).
54. Krosky, P. M., Baek, M. C. & Coen, D. M. Human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77, 905-914 (2003).
55. Wolf, D. G., Courcelle, C. T, Prichard, M. N. & Mocarski, E. S. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl Acad Sci. USA 98, 1895-1900 (2001).
56. Zimmermann, A., Wilts, H., Lenhardt M., Hahn, M. & Mertens, T Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res. 48, 49-60 (2000).
57. Marschall, M. et al. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J. Gen. Viral. 82, 1439-1450 (2001).
58. Marschall, M. et al. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J. Gen. Virol. 83, 1013-1023 (2002).
59. Lalezari, J. P. at al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46, 2969-2976 (2002).
60. Bresnahan, W. A., Boldogh, I., Thompson, E. A. & Albrecht, T. Inhibition of cellular cdk2 activity blocks human cytomegalovirus replication. Virology 231, 239-247 (1997).
61. Schang, L. M. at al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus type 1 by targeting cellular, not viral, proteins. J. Virol. 76, 7874-7882 (2002).
62. Moffat, J., Leisenfelder, S. & Hartigan, A. VZV replication in retinal pigment epithelial cells causes an induction of cyclin-dependent kinase 2 and growth can be blocked by roscovitine, a cdk 2 inhibitor 27th International Herpesvirus Workshop, Abstract 13.15, (Cairns, Australia, 2002).
63. Schang, L. M., Phillips, J. & Schaffer, P. A. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72, 5626-5637 (1998).
64. Zhu, H., Cong, J. P, Yu, D., Breshnahan, W. A. & Shenk, T. E. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc. Natl Acad. Sci. USA 99, 3932-3937 (2002).
65. Amici, C., Belardo, G., Rossi, A., & Santoro, M. G. Activation of IKB kinase by herpes simplex virus type 1. J. Biol. Chem. 276, 28759-28766 (2001).
66. Schang, L. M. Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. 50, 779-792 (2002).
67. Tyring, S., Spruance, S. L., Smith, M, H. & Meng, T. Immunomodulation to decrease recurrences of Herpes genitalis: a dose ranging study of topical resiquimod. Int. J. STD AIDS. 12, Suppl, 2, 151-152 (2001).
68. Higaki, S., Gebhardt, B. M., Lukiw, J., Thompson, H. W. & Hill, J. M. Effect of immunosuppression on gene expression of the HSV-1 latently infected mouse trigeminal ganglion. Invest. Opthalmol. Vis. Sci. 43, 1862-1869 (2002).
69. Kramer, M. F. et al. Host gene expression in murine ganglia latenty infected with herpes simplex virus (HSV). 27th International Herpesvirus Workshop. Abstract 15.09 (Cairns, Australia, 2002).
70. Rickinson, A. B. & Kieff, E. in Fields Virology 4th ed, Vol. 2 (eds Knipe, D. M. et al.) 2572-2627 (Lippincott Williams & Wilkins, Philadelphia, 2001).
71. Kieff, E. & Rickinson, A. B. in Fields Virology 4th ed, Vol. 2 (ads Knipe, D. M. et al.) 2511-2573 (Lippincott Williams & Wilkins, Philadelphia, 2001).
72. Leight, E. R. & Sugden, B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev. Med. Virol. 10, 83-100 (2000).
73. Pagano, J. S., Jimenez, G., Sung, N. S., Raab-Traub, N. & Lin, J. C. Epstein-Barr viral latency and cell immortalization as targets for antisense oligomers. Ann. NYAcad. Sci. 660, 107-116 (1992).
74. Roth, G., Curiel, T & Lacy, J. Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 84, 582-587 (1994).
75. Huang, S., Stupack, D., Mathias, P, Wang, Y. & Nemerow, G. Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Proc. Natl Acad. Sci. USA 94, 8156-8161 (1997).
76. Kenney, J. L., Guinness, M. E., Curiel, T. & Lacy, J. Antisense to the Epstein-Barr virus (EBV-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and Bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 92, 1721-1727 (1998).
77. Cooper, L. & Longnecker, R. Inhibition of host kinase activity altered by the LMP2A signalosome- a therapeutic target for Epstein-Barr virus latency and associated disease. Antiviral Res. 56, 219-231 (2002).